Diadema Partners LP

Diadema Partners LP provides discretionary investment management primarily to private funds and acts as a sub‑advisor to other private funds and separately managed accounts, serving qualified purchasers, institutional investors and high‑net‑worth clients. As of December 31, 2025, the firm reported $397,900,939 in discretionary assets under management and is compensated through management fees and potential performance allocations described in client governing documents.

The firm follows a catalyst‑driven, sector‑focused approach concentrated in the biotech and pharmaceutical subsectors of healthcare, investing in equities, debt and derivatives globally and using options to underwrite outcomes. Its stated process includes the use of leverage and OTC derivatives, application of alternative data and generative‑AI tools in research, and reliance on third‑party External Trading Desks for execution.

Distinctive aspects of the firm include the routine use of borrowing and derivatives in separately managed accounts—practices the brochure highlights in its risk and expense discussions—and explicit references to CFTC filings and related costs, which align with commodity‑pool or trading‑advisor activity. The firm also notes relationships with corporate or business clients in addition to institutional investors, and operates with a compact advisory team managing a material pool of institutional assets.